Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
May 02 2017 - 3:36PM
Vical Incorporated (Nasdaq:VICL) today held its virtual Research
and Development day for investors and analysts. The company
provided an update on its internal programs VL-2397 for invasive
aspergillosis (IA) and the HSV-2 therapeutic vaccine.
VL-2397 – Invasive
Aspergillosis
- The Phase 1 trial of its novel antifungal, VL-2397 was a
randomized, double-blind, placebo-controlled trial designed
to evaluate safety, tolerability and pharmacokinetics of single and
multiple ascending doses of intravenous VL-2397 in 96 healthy
volunteers. Results point to a favorable safety and pharmacokinetic
profile for VL-2397.
- The full data set will be presented on June 2 as one of four
presentations at the ASM Microbe 2017 conference. In preclinical
studies, VL-2397 has demonstrated rapid and potent antifungal
activity against a range of invasive fungal pathogens, including
frequently-occurring Aspergillus species, azole-resistant
Aspergillus fumigatus, Candida glabrata and Cryptococcus
neoformans.
- Our current plan is to conduct a Phase 2 efficacy study to
evaluate VL-2397 for the treatment of invasive aspergillosis and we
are working with our clinical experts and the FDA towards this
objective. The FDA has granted Vical QIDP, Orphan Drug and Fast
Track designations to VL-2397 for the treatment of invasive
aspergillosis. Under the QIDP designation we have been able to
interact intensively with the FDA on the design of the Phase 2
trial. We are exploring an expedited development pathway for
VL-2397.
- The VL-2397 program featured a presentation titled “Impact of
Changing Epidemiology in Invasive Aspergillosis” presented by Dr.
Haran Schlamm, MD, infectious disease specialist and former Senior
Medical Director at Pfizer, responsible for clinical development,
medical and regulatory affairs for Pfizer’s antifungal
portfolio.
HSV-2 – Therapeutic VaccineThe
HSV-2 program featured a presentation titled “Is a Therapeutic
Vaccine Poised to Create a Paradigm Shift in the Management of
HSV-2” by Dr. Anna Wald, MD, MPH, Professor, Department of
Medicine, Epidemiology and Laboratory Medicine at the University of
Washington and Lead Investigator in the ongoing Phase 2 trial. The
event also provided a comprehensive overview of Vical’s product
pipeline which included a detailed review of our HSV-2 program
given by Dr. Anza Mammen.
A replay of the call will be available for 48
hours beginning about two hours after the call. To listen to the
replay, dial (719) 457-0820 (preferred) or (888) 203-1112
(toll-free) and enter replay passcode 9084195. The call will also
be archived through the events page at www.vical.com. For further
information, contact Vical’s Investor Relations department by phone
at (858) 646-1127 or by e-mail at ir@vical.com.
About VicalVical develops
biopharmaceutical products for the prevention and treatment of
chronic or life-threatening infectious diseases, based on its
patented DNA delivery technologies and other therapeutic
approaches. Additional information on Vical is available at
www.vical.com.
Contact:
Tony Ramos
(858) 646-1127
Website: www.vical.com
Vical (NASDAQ:VICL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vical (NASDAQ:VICL)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Vical Inc (NASDAQ): 0 recent articles
More News Articles